such as industry testing , compliance , and quality management into the hemp industry .
CONCLUSION
The global experience of growth in the hemp sector points to exciting opportunities for the New Zealand Industrial Hemp Sector , both in the domestic market and for our exports .
The process in other countries of liberalisation of laws blocking CBD extraction and products , as discussed above , demonstrates to New Zealand legislators and regulators that there are a range of different approaches which will allow growth to occur . To enable the industrial hemp sector in New Zealand is to allow agricultural growth at an exponential rate .
History also clearly shows that being a signatory to the United Nations Single Convention on Narcotics 1961 has not hindered any countries in their amendment , re-definition or complete removal of the prohibition in that Convention on cannabis sativa . At most it has visited a little disapproval on those countries which
Investor Report Industrial Hemp Sector New Zealand ’ s New Export Opportunity 2020
have liberalised marijuana , but that does not appear to have deterred them , nor has it changed their status in regard to membership as a Convention signatory .
Even the World Health Organisation has recently recommended to the United Nations that cannabis be reclassified , by removal from Schedule IV of the Single Convention , which is the most restrictive level of the Convention ( and includes heroin ). The recommendation is that it should be maintained under a less restrictive level of control than Schedule I , which applies to “ harmful psychoactive substances ” which could have a medical use ( such as morphine ).
In regard to CBD , the WHO recommends that preparations containing predominantly CBD and with no more than 0.2 % THC should not be placed under international drug control , and that this should be expressly stated in the Single Convention . This recommendation is based on reviews by the WHO ’ s Expert Committee on Drug Dependence on cannabis and cannabis related substances ( including CBD ) - which found CBD to be a relatively safe drug .
Interestingly , one commentator ’ s view was that “ the WHO ’ s slowmoving suggestions may be obsolete by the time they are implemented , given that more progressive organizations are so far ahead ”. ( 13 )
Australia is an interesting example of a country which is moving ahead with the concept of down-scheduling low dose CBD , a move which has been proposed by the Therapeutic Goods Agency . In proposing this course , reference is expressly made to WHO ’ s recommendation that CBD should not be placed under international drug control . This is of particular interest to New Zealand given our Trans-Tasman relationship and the harmonisation of various standards including food standards relationship and the harmonisation of various standards including food standards . For the New Zealand hemp industry , and those lawmakers who have the power to remove the constraints on its growth , the question that is begged by this review of the global growth and opportunity in the hemp industry is :
29
“ If not now then when ?”